PDS Biotechnology Corporation
Climate Impact & Sustainability Data (2020, 2020-09, 2024)
Reporting Period: 2020
Environmental Metrics
Social Achievements
- Implemented proactive measures to protect employee health and safety during the COVID-19 pandemic.
- Provides employees with market salaries and bonuses, opportunities for equity ownership, development programs, and a robust employment package promoting well-being.
Climate Goals & Targets
Environmental Challenges
- COVID-19 pandemic impacted clinical trial operations, leading to delays in two out of three PDS0101 clinical trials.
- Intense competition in the biotechnology and pharmaceutical industries.
- Uncertainty regarding coverage and reimbursement for PDS0101.
- Potential for product liability lawsuits.
- Need for additional capital to fund operations.
Mitigation Strategies
- Implemented measures to address COVID-19 challenges, including remote monitoring of patients and sites.
- Focus on developing superior immunotherapies and obtaining regulatory approvals.
- Exploring strategic collaborations and licensing agreements.
- Maintaining product liability insurance coverage.
- Seeking additional funding through equity and debt financings.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2020-09
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- COVID-19 pandemic delaying clinical trials and impacting enrollment pace.
- Potential for future delays due to patients avoiding healthcare facilities and limitations on clinical trial staff access.
Mitigation Strategies
- Initiated delayed studies despite pandemic challenges.
- Implemented work-from-home policy for most staff.
- Implemented procedures in accordance with FDA guidance on conducting clinical trials during the COVID-19 pandemic (remote monitoring, etc.).